Gastric Cancer and Imaging Biomarkers: Part 1 - a Critical Review of DW-MRI and CE-MDCT Findings

Overview

Journal Eur Radiol

Specialty Radiology

Date 2018 Oct 4

PMID 30280246

Citations 29

Authors

Francesco Giganti

Lei Tang

Hideo Baba

Affiliations

Soon will be listed here.

Abstract

The current standard of care for gastric cancer imaging includes heterogeneity in image acquisition techniques and qualitative image interpretation. In addition to qualitative assessment, several imaging techniques, including diffusion-weighted magnetic resonance imaging (DW-MRI), contrast-enhanced multidetector computed tomography (CE-MDCT), dynamic-contrast enhanced MRI and 18F-fluorodeoxyglucose positron emission tomography, can allow quantitative analysis. However, so far there is no consensus regarding the application of functional imaging in the management of gastric cancer. The aim of this article is to specifically review two promising biomarkers for gastric cancer with reasonable spatial resolution: the apparent diffusion coefficient (ADC) from DW-MRI and textural features from CE-MDCT. We searched MEDLINE/ PubMed for manuscripts published from inception to 6 February 2018. Initially, we searched for (gastric cancer OR gastric tumour) AND diffusion weighted magnetic resonance imaging. Then, we searched for (gastric cancer OR gastric tumour) AND texture analysis AND computed tomography. We collated the results from the studies related to this query. There is evidence that: (1) the ADC is a promising biomarker for the evaluation of the aggressiveness (T and N stage), treatment response and prognosis of gastric cancer; (2) textural features are related to the degree of differentiation, Lauren classification, treatment response and prognosis of gastric cancer. We conclude that these imaging biomarkers hold promise as effective additional tools in the diagnostic pathway of gastric cancer and may facilitate the multidisciplinary work between the radiologist and clinician, and across different institutions, to provide a greater biological understanding of gastric cancer. KEY POINTS: • Quantitative imaging is the extraction of quantifiable features from medical images for the assessment of normal or pathological conditions and represents a promising area for gastric cancer. • Quantitative analysis from CE-MDCT and DW-MRI allows the extrapolation of multiple imaging biomarkers. • ADC from DW-MRI and CE- MDCT-based texture features are non-invasive, quantitative imaging biomarkers that hold promise in the evaluation of the aggressiveness, treatment response and prognosis of gastric cancer.

Citing Articles

Diffusion-weighted MRI of advanced gastric cancer: correlations of the apparent diffusion coefficient with Borrmann classification, proliferation and aggressiveness.

Ma L, Guo L, Zhu X, Yi X, Du W, Lan X Abdom Radiol (NY). 2025; .

PMID: 39815027 DOI: 10.1007/s00261-024-04718-6.

Hepatoid adenocarcinoma of the stomach: discrimination from conventional gastric adenocarcinoma with a computed tomography-based radiomics nomogram.

Gu X, Rong J, Zhu L, Dai Z, Ren S, Chen J J Gastrointest Oncol. 2024; 15(5):2041-2052.

PMID: 39554578 PMC: 11565099. DOI: 10.21037/jgo-24-210.

Predicting tumor invasion depth in gastric cancer: developing and validating multivariate models incorporating preoperative IVIM-DWI parameters and MRI morphological characteristics.

Hong Y, Li X, Liu Z, Fu C, Nie M, Chen C Eur J Med Res. 2024; 29(1):431.

PMID: 39175075 PMC: 11340138. DOI: 10.1186/s40001-024-02017-w.

Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.

Sun J, Wang Z, Zhu H, Yang Q, Sun Y J Imaging Inform Med. 2024; 37(6):2910-2919.

PMID: 38886288 PMC: 11612076. DOI: 10.1007/s10278-024-01148-0.

A nomogram model of spectral CT quantitative parameters and clinical characteristics predicting lymphovascular invasion of gastric cancer.

Tong Y, Ye X, Chen Y, You Y, Zhang H, Chen S Heliyon. 2024; 10(7):e29214.

PMID: 38601586 PMC: 11004867. DOI: 10.1016/j.heliyon.2024.e29214.

References

van der Meel R, Gallagher W, Oliveira S, OConnor A, Schiffelers R, Byrne A . Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today. 2009; 15(3-4):102-14. DOI: 10.1016/j.drudis.2009.12.003. View

. ESR Position Paper on Imaging Biobanks. Insights Imaging. 2015; 6(4):403-10. PMC: 4519817. DOI: 10.1007/s13244-015-0409-x. View

Giganti F, De Cobelli F, Canevari C, Orsenigo E, Gallivanone F, Esposito A . Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J Magn Reson Imaging. 2013; 40(5):1147-57. DOI: 10.1002/jmri.24464. View

Lubner M, Smith A, Sandrasegaran K, Sahani D, Pickhardt P . CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges. Radiographics. 2017; 37(5):1483-1503. DOI: 10.1148/rg.2017170056. View

Kang B, Kim J, Kim K, Lee D, Baek S, Lee S . Value of the dynamic and delayed MR sequence with Gd-DTPA in the T-staging of stomach cancer: correlation with the histopathology. Abdom Imaging. 2000; 25(1):14-24. DOI: 10.1007/s002619910003. View

Mills A, Sakai O, Anderson S, Jara H . Principles of Quantitative MR Imaging with Illustrated Review of Applicable Modular Pulse Diagrams. Radiographics. 2017; 37(7):2083-2105. DOI: 10.1148/rg.2017160099. View

Cheng J, Wang Y, Deng J, McCarthy R, Wang G, Wang H . Discrimination of metastatic lymph nodes in patients with gastric carcinoma using diffusion-weighted imaging. J Magn Reson Imaging. 2012; 37(6):1436-44. DOI: 10.1002/jmri.23925. View

Abramson R, Arlinghaus L, Dula A, Quarles C, Stokes A, Weis J . MR Imaging Biomarkers in Oncology Clinical Trials. Magn Reson Imaging Clin N Am. 2015; 24(1):11-29. PMC: 4667554. DOI: 10.1016/j.mric.2015.08.002. View

Glunde K, Pathak A, Bhujwalla Z . Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med. 2007; 13(7):287-97. DOI: 10.1016/j.molmed.2007.05.002. View

10.

Waterton J, McShane L, OConnor J . Imaging biomarkers exist and they underpin clinical decision-making. Nat Rev Clin Oncol. 2017; 14(7):452. DOI: 10.1038/nrclinonc.2017.84. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Buckler A, Bresolin L, Reed Dunnick N, Sullivan D . A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology. 2011; 258(3):906-14. DOI: 10.1148/radiol.10100799. View

13.

Zhong J, Zhao W, Ma W, Ren F, Qi S, Zheng J . DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases. Medicine (Baltimore). 2016; 95(13):e3236. PMC: 4998555. DOI: 10.1097/MD.0000000000003236. View

14.

Pinheiro D, Ferreira W, Leao Barros M, Araujo M, Rodrigues-Antunes S, Borges B . Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications. World J Gastroenterol. 2014; 20(33):11574-85. PMC: 4155351. DOI: 10.3748/wjg.v20.i33.11574. View

15.

Joo I, Lee J, Kim J, Shin C, Han J, Choi B . Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer. J Magn Reson Imaging. 2014; 41(3):814-21. DOI: 10.1002/jmri.24586. View

16.

Ganeshan B, Miles K . Quantifying tumour heterogeneity with CT. Cancer Imaging. 2013; 13:140-9. PMC: 3613789. DOI: 10.1102/1470-7330.2013.0015. View

17.

Lee D, Kim S, Im S, Oh D, Kim T, Han J . Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. Eur Radiol. 2015; 26(8):2771-8. DOI: 10.1007/s00330-015-4105-5. View

18.

Davnall F, Yip C, Ljungqvist G, Selmi M, Ng F, Sanghera B . Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. Insights Imaging. 2012; 3(6):573-89. PMC: 3505569. DOI: 10.1007/s13244-012-0196-6. View

19.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

20.

Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View